Novo Nordisk shares pop 10% on early-stage weight loss drug trial results
January 24, 2025 at 06:02 AM EST
The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
|
|
|